Rapid test to identity myeloma kidney by measurement of serum free light chains

J. Campbell, A. Stride, M. Cobbold, Y. Wang, M. Goodall, S. Bonney, A. Chamba, T. Plant, Z. Afzal, R. Jefferis, M. Drayson

Research output: Contribution to journalMeeting abstract

7 Citations (Scopus)

Abstract

Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity
LanguageEnglish
Pages253-254
Number of pages2
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
StatusPublished - 1 Apr 2013

Fingerprint

Point-of-Care Systems
Kidney
Light
Serum
Urine
Immunoglobulin Light Chains
Paraproteinemias
Acute Kidney Injury
Immunoglobulins
Early Diagnosis
Biomarkers
Monoclonal Antibodies
Antibodies
Proteins

Keywords

  • immunoglobulin
  • monoclonal antibody
  • antigen
  • protein
  • antibody
  • myeloma
  • serum
  • kidney
  • light chain
  • identity
  • workshop
  • rapid test
  • human
  • urine
  • patient
  • blood
  • kidney injury
  • risk
  • early diagnosis
  • clinical practice
  • turnaround time
  • laboratory
  • plasma cell dyscrasia
  • cross reaction
  • competitive inhibition
  • donor
  • acute kidney failure

Cite this

Campbell, J., Stride, A., Cobbold, M., Wang, Y., Goodall, M., Bonney, S., ... Drayson, M. (2013). Rapid test to identity myeloma kidney by measurement of serum free light chains. Clinical Lymphoma, Myeloma and Leukemia, 13, 253-254.

Rapid test to identity myeloma kidney by measurement of serum free light chains. / Campbell, J.; Stride, A.; Cobbold, M.; Wang, Y.; Goodall, M.; Bonney, S.; Chamba, A.; Plant, T.; Afzal, Z.; Jefferis, R.; Drayson, M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, 01.04.2013, p. 253-254.

Research output: Contribution to journalMeeting abstract

Campbell, J, Stride, A, Cobbold, M, Wang, Y, Goodall, M, Bonney, S, Chamba, A, Plant, T, Afzal, Z, Jefferis, R & Drayson, M 2013, 'Rapid test to identity myeloma kidney by measurement of serum free light chains', Clinical Lymphoma, Myeloma and Leukemia, vol. 13, pp. 253-254.
Campbell, J. ; Stride, A. ; Cobbold, M. ; Wang, Y. ; Goodall, M. ; Bonney, S. ; Chamba, A. ; Plant, T. ; Afzal, Z. ; Jefferis, R. ; Drayson, M. / Rapid test to identity myeloma kidney by measurement of serum free light chains. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13. pp. 253-254.
@article{aa20d606716a4fbea2fddfb9eee97b63,
title = "Rapid test to identity myeloma kidney by measurement of serum free light chains",
abstract = "Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity",
keywords = "immunoglobulin, monoclonal antibody, antigen, protein, antibody, myeloma, serum, kidney, light chain, identity, workshop, rapid test, human, urine, patient, blood, kidney injury, risk, early diagnosis, clinical practice, turnaround time, laboratory, plasma cell dyscrasia, cross reaction, competitive inhibition, donor, acute kidney failure",
author = "J. Campbell and A. Stride and M. Cobbold and Y. Wang and M. Goodall and S. Bonney and A. Chamba and T. Plant and Z. Afzal and R. Jefferis and M. Drayson",
year = "2013",
month = "4",
day = "1",
language = "English",
volume = "13",
pages = "253--254",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Elsevier",

}

TY - JOUR

T1 - Rapid test to identity myeloma kidney by measurement of serum free light chains

AU - Campbell, J.

AU - Stride, A.

AU - Cobbold, M.

AU - Wang, Y.

AU - Goodall, M.

AU - Bonney, S.

AU - Chamba, A.

AU - Plant, T.

AU - Afzal, Z.

AU - Jefferis, R.

AU - Drayson, M.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity

AB - Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity

KW - immunoglobulin

KW - monoclonal antibody

KW - antigen

KW - protein

KW - antibody

KW - myeloma

KW - serum

KW - kidney

KW - light chain

KW - identity

KW - workshop

KW - rapid test

KW - human

KW - urine

KW - patient

KW - blood

KW - kidney injury

KW - risk

KW - early diagnosis

KW - clinical practice

KW - turnaround time

KW - laboratory

KW - plasma cell dyscrasia

KW - cross reaction

KW - competitive inhibition

KW - donor

KW - acute kidney failure

M3 - Meeting abstract

VL - 13

SP - 253

EP - 254

JO - Clinical Lymphoma, Myeloma and Leukemia

T2 - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

ER -